Effectiveness of tildrakizumab 200 mg: an Italian multicenter study

Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Annunziata Dattola, Nicoletta Bernardini, Francesca Svara, Anna Balato, Giacomo Caldarola, Domenico D’Amico, Clara De Simone, Eugenia Veronica Di Brizzi, Maria Esposito, Claudia Giofrè, Domenico Giordano, Claudio Guarneri, Francesco Loconsole, Viviana Lora, Gaia Moretta, Diego Orsini, Severino Persechino, Concetta Potenza, Simone Ragonesi, Giovanni Pellacani, Ketty Peris, Maria Concetta Fargnoli, Antonio Giovanni Richetta
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Taylor & Francis Group 2024-12-01
Σειρά:	Journal of Dermatological Treatment
Θέματα:	Effectiveness psoriasis tildrakizumab tildrakizumab 200 mg anti-IL23
Διαθέσιμο Online:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2420825
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!